February 11 - 14, 2016
Hyatt Regency New Orleans
New Orleans, Louisiana, USA
Abstract submission deadline: Tuesday, December 1
Advance registration deadline: Friday, January 8
Conference Co-ChairpersonsManuel Hidalgo, Beth Israel Deaconess Medical Center, Boston, MassachusettsHans Clevers, Hubrecht Institute, Sciences & University Medical Centre Utrecht, and Princess Maxima Center for Pediatric Oncology, Utrecht, the NetherlandsS. Gail Eckhardt, University of Colorado Cancer Center, Aurora, ColoradoJoan Seoane, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
Patient-derived cancer models have become one (if not the preferred) approach for preclinical drug development and biomarker discovery. More than 20 academic centers around the world are now building large collections of well-characterized models that are an important platform for cancer biology studies and personalized medicine applications. The increased interest in this area has been a subject addressed in several recent meetings, but this will be the first program focused solely on patient-derived cancer models and their applications in basic, translational, and clinical research.
This multilayered program includes leaders from academia, pharmaceutical industry, biotech companies, and regulatory agencies that will discuss technical and methodological issues regarding PDX development; disease-oriented collections; newer approaches to PDX development; applications in translational cancer research; personalized medicine opportunities; and U.S. and E.U.-based network initiatives.
Continuing Medical Education Activity AMA PRA Category 1 CreditsTM available#AACRpdx16